司美格鲁肽在肥胖相关射血分数保留心衰合并房颤患者中的效果:STEP-HFpEF项目分析
本分析汇总STEP-HFpEF与STEP-HFpEF DM试验中1145例肥胖相关HFpEF患者,45%有房颤史。司美格鲁肽2.4mg每周一次治疗52周,在有无房颤患者中均改善心衰症状、体力受限、运动功能,并降低体重、CRP和NT-proBNP;有房颤者KCCQ-CSS和分层复合终点的改善幅度更大。
要点
- 肥胖相关HFpEF患者中近半数合并房颤,且房颤者心衰更晚期。
- 司美格鲁肽改善心衰症状和运动功能,无论有无房颤及房颤类型。
- 有房颤者司美格鲁肽改善KCCQ-CSS和复合终点的幅度更大。
核心结论
- 在STEP-HFpEF项目中,司美格鲁肽2.4mg每周一次在有无房颤及不同房颤类型的肥胖相关HFpEF患者中均显著改善心衰相关症状、体力受限和运动功能,并降低体重、CRP和NT-proBNP。
- 有房颤史者接受司美格鲁肽后KCCQ-CSS和分层复合终点的改善幅度较无房颤者更大。
研究设计与样本
- 本研究为STEP-HFpEF和STEP-HFpEF DM两项试验汇总数据的二次分析。
- 纳入心衰、左心室射血分数≥45%、体重指数≥30 kg/m2、KCCQ-CSS<90分的患者,随机1:1接受司美格鲁肽2.4mg每周一次或安慰剂治疗52周。
主要发现
- 共1145例参与者,518例(45%)有房颤史(40%阵发性、24%持续性、35%永久性),627例(55%)无房颤史。
- 有房颤者较无房颤者年龄更大、男性更多、NT-proBNP更高、NYHA III级比例更高、抗血栓药、β受体阻滞剂和利尿剂使用更多。
- 司美格鲁肽组KCCQ-CSS改善在房颤者中为11.5分(95%CI: 8.3-14.8),无房颤者为4.3分(95%CI: 1.3-7.2),P交互=0.001。
- 分层复合终点胜率在房颤者为2.25(95%CI: 1.79-2.83),无房颤者为1.30(95%CI: 1.06-1.59),P交互<0.001。
- KCCQ-CSS改善≥5、≥10、≥15、≥20分的患者比例在房颤者中更高(所有P交互<0.05)。
关键数值与推荐
- 司美格鲁肽2.4mg每周一次治疗52周。
- 双主要终点为KCCQ-CSS变化和体重百分比变化。
- 确认性次要终点包括6分钟步行距离变化、分层复合终点(全因死亡、心衰事件、KCCQ-CSS变化阈值和6分钟步行距离)和CRP。
- 探索性终点为NT-proBNP变化。
临床怎么用
- 对于肥胖相关HFpEF患者,无论有无房颤病史,均可考虑使用司美格鲁肽2.4mg每周一次以改善心衰症状、体力受限和运动功能,并降低体重。
- 合并房颤的肥胖相关HFpEF患者可能从司美格鲁肽治疗中获得更明显的症状和体力受限改善。
局限性
- 本研究为二次分析,房颤史由研究者报告。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Obesity is a key factor in the development and progression of both heart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF). In the STEP-HFpEF Program (comprising the STEP-HFpEF [Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity] and STEP-HFpEF DM [Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes] trials), once-weekly semaglutide 2.4 mg improved HF-related symptoms, physical limitations, and exercise function and reduced body weight in patients with obesity-related HFpEF. Whether the effects of semaglutide in this patient group differ in participants with and without AF (and across various AF types) has not been fully examined. OBJECTIVES: The goals of this study were: 1) to evaluate baseline characteristics and clinical features of patients with obesity-related HFpEF with and without a history of AF; and 2) to determine if the efficacy of semaglutide across all key trial outcomes are influenced by baseline history of AF (and AF types) in the STEP-HFpEF Program. METHODS: This was a secondary analysis of pooled data from the STEP-HFpEF and STEP-HFpEF DM trials. Patients with heart failure, left ventricular ejection fraction ≥45%, body mass index ≥30 kg/m2, and Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS) <90 points were randomized 1:1 to receive once-weekly semaglutide 2.4 mg or matching placebo for 52 weeks. Dual primary endpoints (change in KCCQ-CSS and percent change in body weight), confirmatory secondary endpoints (change in 6-minute walk distance; hierarchical composite endpoint comprising all-cause death, HF events, thresholds of change in KCCQ-CSS, and 6-minute walk distance; and C-reactive protein [CRP]), and exploratory endpoint (change in N-terminal pro-B-type natriuretic peptide [NT-proBNP]) were examined according to investigator-reported history of AF (yes/no). Responder analyses examined the proportions of patients who experienced a ≥5-, ≥10, ≥15, and ≥20-point improvement in KCCQ-CSS per history of AF. RESULTS: Of the 1,145 participants, 518 (45%) had a history of AF (40% paroxysmal, 24% persistent AF, and 35% permanent AF) and 627 (55%) did not. Participants with (vs without) AF were older, more often male, had higher NT-proBNP levels, included a higher proportion of those with NYHA functional class III symptoms, and used more antithrombotic therapies, beta-blockers, and diuretics. Semaglutide led to larger improvements in KCCQ-CSS (11.5 points [95% CI: 8.3-14.8] vs 4.3 points [95% CI: 1.3-7.2]; P interaction = 0.001) and the hierarchal composite endpoint (win ratio of 2.25 [95% CI: 1.79-2.83] vs 1.30 [95% CI: 1.06-1.59]; P interaction < 0.001) in participants with AF vs without AF, respectively. The proportions of patients receiving semaglutide vs those receiving placebo experiencing ≥5-, ≥10-, ≥15-, and ≥20-point improvement in KCCQ-CSS were also higher in those with (vs without) AF (all P interaction values <0.05). Semaglutide consistently reduced CRP, NT-proBNP, and body weight regardless of AF status (all P interaction values not significant). There were fewer serious adverse events and serious cardiac disorders in participants treated with semaglutide vs placebo irrespective of AF history. CONCLUSIONS: In the STEP-HFpEF Program, AF was observed in nearly one-half of patients with obesity-related HFpEF and was associated with several features of more advanced HF. Treatment with semaglutide led to significant improvements in HF-related symptoms, physical limitations, and exercise function, as well as reductions in weight, CRP, and NT-proBNP in people with and without AF and across AF types. The magnitude of semaglutide-mediated improvements in HF-related symptoms and physical limitations was more pronounced in those with AF vs without AF at baseline. (Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity [STEP-HFpEF; NCT04788511]; Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes [STEP-HFpEF DM; NCT04916470]).
引用
- Verma S, Butler J, Borlaug BA, et al. Atrial Fibrillation and Semaglutide Effects in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Program. J Am Coll Cardiol. 2024. PMID: 39217565. doi:10.1016/j.jacc.2024.08.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。